Women’s Health Is Not a Niche. It Is a Mispriced Market.

In over two decades of advising private wealth on capital allocation, the most valuable signal is this: The best opportunities are sometimes not where fundamentals are misunderstood, but where the lens used to evaluate the opportunities is flawed. Women’s health is the clearest example I have encountered.

Less than 2% of private healthcare funding goes to women-specific conditions. Women make over 80% of household healthcare decisions. They are the fastest-growing cohort of wealth holders globally, with an estimated $124 trillion transferring to women over the coming decade.

These are not separate data points. They form what I think of as the Wealth–Health Convergence; a single capital cycle in which decision-making power, capital ownership, and unmet medical need reinforce each other. The gap between them represents one of the most significant mispricings in modern markets.

For decades, that gap persisted for structural reasons. Foundational medical research was conducted primarily on male bodies. Clinical trials routinely excluded women of reproductive age. The evidence base that informs reimbursement, product development, and ultimately investment decisions was built on incomplete data. Investors, in turn, allocated capital based on what could be measured and modelled. Entire categories of demand remained partially invisible.

Markets do not ignore value indefinitely. But they can misprice it for a long time when the underlying data is flawed. What is changing now is not the existence of demand, but the ability to see and validate it.

Advances in diagnostics, telehealth, and data infrastructure have materially lowered the cost of proving demand. Conditions that were previously underdiagnosed or dismissed are becoming measurable, trackable, and commercially addressable. The distance between unmet need and investable opportunity is narrowing.

Governments are also responding. Last month, the UK government published its renewed Women’s Health Strategy with the Health Secretary Wes Streeting saying the NHS “too often gaslights women, treating their pain as an inconvenience.” The UK’s renewed Women’s Health Strategy is a genuine step forward. But the more important question for investors is not whether it is good policy. It is what that policy signals about where capital moves next.

That shift is already underway. The capital base itself is shifting.  The Great Wealth Transfer is not simply a change in who owns assets. It is a change in how capital is allocated. For the first time at scale, the person making healthcare decisions is increasingly the same person directing capital. That alignment matters.

Women inheriting and building wealth today are not a passive audience for financial products designed around someone else’s experience. They are principals in the allocation process, often with decades of direct exposure to gaps in the healthcare system. Lived experience is moving closer to capital allocation decisions, and that changes how markets interpret demand.

This is where the Wealth–Health Convergence becomes investable.

When improving evidence meets a reorienting capital base, the result is not gradual change. It is repricing. Better diagnostics increase detection rates, expanding the addressable market. More targeted treatments attract capital as clinical pathways become clearer. Commercial models that once appeared niche begin to demonstrate scale. What emerges is not a new market, but a clearer view of an existing one.

Yet much of the investment community still treats women’s health as a vertical, often labelled “Femtech”,  rather than as a cross-cutting lens across healthcare. This framing underestimates both the size and the integration of the opportunity. Many of the largest healthcare markets, including cardiovascular disease, neurodegeneration, and metabolic disorders, are being reassessed as new evidence reveals how risk, symptoms, and disease progression differ between women and men, and across different stages of life.

Reframing women’s health as an investment category is not about creating a specialised segment. It is about correcting an analytical blind spot that has affected how multiple sectors are priced.

For founders, this shift is critical. Innovation without access to capital stalls at proof of concept. The diagnostics, therapeutics, and digital platforms being built in women’s health are reaching scale at the same moment that the frameworks used to evaluate them are improving. The window between those two developments is narrowing.

For investors, the implication is straightforward. The opportunity is not in waiting for the category to be fully validated. By the time consensus forms, the mispricing has largely corrected. The advantage lies in building the analytical frameworks early; understanding the data gaps, accessing differentiated deal flow, and constructing portfolios that reflect where demand is becoming visible, not where it has already been priced.